Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Capecitabine-Associated Terminal Ileitis

Capecitabine-Associated Terminal Ileitis Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecitabine-induced terminal ileitis is likely to be underreported. It should be considered more often as a cause of severe and atypical complaints of diarrhea during treatment with capecitabine or other 5-fluorouracil agents. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Case Reports in Oncology Karger

Capecitabine-Associated Terminal Ileitis

Download PDF
6 pages

Loading next page...
 
/lp/karger/capecitabine-associated-terminal-ileitis-LkUlZFm8qB

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2018 The Author(s). Published by S. Karger AG, Basel
eISSN
1662-6575
DOI
10.1159/000492781
Publisher site
See Article on Publisher Site

Abstract

Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecitabine-induced terminal ileitis is likely to be underreported. It should be considered more often as a cause of severe and atypical complaints of diarrhea during treatment with capecitabine or other 5-fluorouracil agents.

Journal

Case Reports in Oncology – Karger

Published: Jan 1, 2018

Keywords: Colorectal cancer; Capecitabine; Fluoropyrimidine; Terminal Ileitis; Diarrhea; Adverse event

References

  • Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials
    Iacovelli, R; Pietrantonio, F; Palazzo, A; Maggi, C; Ricchini, F; de Braud, F
  • Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration
    Ezzeldin, H; Diasio, R
  • Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
    Baird, R; Biondo, A; Chhaya, V; McLachlan, J; Karpathakis, A; Rahman, S
  • Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum
    Ikuno, N; Soda, H; Watanabe, M; Oka, M
  • Recommended guidelines for the treatment of cancer treatment-induced diarrhea
    Benson, AB; Ajani, JA; Catalano, RB; Engelking, C; Kornblau, SM; Martenson, JA
  • Ileitis secondary to oral capecitabine treatment?
    Radwan, R; Namelo, WC; Robinson, M; Brewster, AE; Williams, GL
  • [Ileitis following capecitabine use]
    Bouma, G; Imholz, AL
  • Capecitabine-induced terminal ileitis
    Al-Gahmi, AM; Kerr, IG; Zekri, JM; Zagnoon, AA
  • Severe ileitis associated with capecitabine: two case reports and review of the literature
    Lee, SF; Chiang, CL; Lee, AS; Wong, FC; Tung, SY
  • Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group
    Kwakman, JJ; Simkens, LH; van Rooijen, JM; van de Wouw, AJ; Ten Tije, AJ; Creemers, GJ
  • TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
    Yoshino, T; Mizunuma, N; Yamazaki, K; Nishina, T; Komatsu, Y; Baba, H
  • Randomized trial of TAS-102 for refractory metastatic colorectal cancer
    Mayer, RJ; Van Cutsem, E; Falcone, A; Yoshino, T; Garcia-Carbonero, R; Mizunuma, N